Global Blood Therapeutics Sinks on Secondary Offering
Global Blood Therapeutics has filed with the SEC regarding a secondary offering valued up to $100 million.
Global Blood Therapeutics has filed with the SEC regarding a secondary offering valued up to $100 million.
Mednax has announced that it will acquire Cardon Outreach, one of the nation's largest providers of integraded revenue cycle management services.
Symantec has announced that it has entered into a definitive agreement to acquire Blue Coat for roughly more than $4 billion in cash.
Shares of Marinus Pharmaceuticals tumbled Monday morning after the company gave an update on top-line results from a Phase 3 clinical trial.
Eleven Biotherapeutics watched its shares climb early on Monday morning following a key FDA submission.
Although the broad markets were at their highest levels on the year, some companies held them back from pushing even higher.
Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even unfavorable clinical trial updates.
We only have a few major companies are expected to share their latest results this coming week. Coincidentally, all of these companies are reporting on Thursday.
The SEC has announced fraud charges and an asset freeze against a Connecticut man accused of misleading people into investing in his company, then taking their money for his personal use.
Sophiris Bio shares absolutely skyrocketed on Friday following positive results from its Phase 2a proof of concept study of topsalysin in localized prostate cancer.
Merck and Afferent Pharmaceuticals reportedly have signed a definitive agreement under which the former will acquire the latter.
Shares of Global Blood Therapeutics saw a handy gain going into the weekend following positive results from its mid-stage clinical trial.
H&R Block reported better-than-expected fiscal fourth-quarter financial results after the markets closed on Thursday.
A former consultant to two China-based private equity firms has agreed to pay over $756,000 in order to settle SEC insider trading charges.
The May 31 short interest data have been compared with the previous figures, and short interest moves for the selected cybersecurity stocks were mixed.
The May 31 short interest data have been compared with the previous report. Short interest decreased in most of these selected social media stocks.
The May 31 short interest data have been compared with the previous figures, and short interest for most of the selected oil stocks decreased.
The May 31 short interest data have been compared with the previous report. Short interest largely was mixed in these selected semiconductor stocks.
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.